Glenmark Pharmaceuticals S.A.
Records under this name other than the patents Glenmark Pharmaceuticals S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Back to Glenmark Pharmaceuticals S.A.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,267,891 | FC Variant Antibodies and Their Uses Formerly held In force · High confidence | In force | High confidence | |
| US 8,975,376 | ANTI-ALPHA2 Integrin Antibodies and Their Uses Formerly held In force · High confidence | In force | High confidence | |
| US 9,683,052 | Hetero-dimeric immunoglobulins Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,683,053 | Hetero-dimeric immunoglobulins Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,748,585 | Antibodies that bind to OX40 and their uses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,407,839 | Antibodies that bind to OX40 and their uses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,281,169 | Antibodies that bind to OX40 and their uses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,493,563 | Production of T cell retargeting hetero-dimeric immunoglobulins Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,851,502 | Production of T cell retargeting hetero-dimeric immunoglobulins Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,006,367 | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production Formerly held In force · From the USPTO record | In force | From the USPTO record |